ChemicalBook > Product Catalog >API >Antineoplastic agents >Other antineoplastic Drugs >Cediranib

Cediranib

Cediranib Suppliers list
Company Name: Jinan Trio PharmaTech Co., Ltd.  Gold
Tel:+86 (531) 88811783;
Email:sales@trio-pharmatech.com (International market);trio@trio-pharmatech.com(Domestic market)
Products Intro:Product Name:Cediranib (AZD2171)
CAS:288383-20-0
Purity:99% Package:5g, 10g, 25g, 50g,100g,
Company Name: Shanghai Tombiopharma Chemical Co. Ltd.  Gold
Tel:15307133740
Email:tombiopharma@163.com
Products Intro:Product Name:4-((4-fluoro-2-Methyl-1H-indol-5-yl)oxy)-6-Methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
CAS:288383-20-0
Purity:97% HPLC Package:10g;100g;1kg;10kg
Company Name: BIO-PHARMACY (Wuhan) Co., Ltd.  Gold
Tel:0711-5919292 15307133740
Email:3451683016@qq.com
Products Intro:Product Name:Cediranib
CAS:288383-20-0
Purity:99% HPLC Package:100g,1kg
Company Name: Shanghai Boyle Chemical Co., Ltd.  
Tel:86-21-50180596
Email:sales@boylechem.com
Products Intro:Product Name:Cediranib
CAS:288383-20-0
Company Name: Hangzhou Zyter Biological & Chemical Technology Co., Ltd.  
Tel:0086-18858184290
Email:sales@zyterpharm.com
Products Intro:Product Name:Cediranib
CAS:288383-20-0
Purity:99% Package:1g,5g,10g,100g,1kg
Cediranib Basic information
Anticancer drugs
Product Name:Cediranib
Synonyms:Cediranib;4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline;Cadiranib (AZD2171);Cediranib(AZD2171);AZD2171;Recentin;Cadiranib;Cediranib R
CAS:288383-20-0
MF:C25H27FN4O3
MW:450.51
EINECS:
Product Categories:APIs;Antineoplastic;Inhibitors
Mol File:288383-20-0.mol
Cediranib Structure
Cediranib Chemical Properties
density 1.285
Safety Information
MSDS Information
Cediranib Usage And Synthesis
Anticancer drugsCediranib is an oral anticancer drug , it is successfully developed by the US AstraZeneca company , its trade name is recentin, this product is an efficient VEGFR tyrosine kinase inhibitor, it is capable of inhibiting all known VEGFR tyrosine kinases ( including VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR). Cediranib can inhibit VEGF-induced angiogenesis, neovascularization survival and human tumor xenograft cell growth.Clinical trail phase I for non-small cell lung cancer (abbreviated NSCLC) patients shows that cediranib in combination with PC programs has a significant antitumor effect . Clinical trail phaseⅡ/Ⅲ BR24 focuses on using cediranib 30mg as a first-line treatment of NSCLC ,which demonstrates that it has anti-tumor effect, but it has a higher incidence of adverse events, including diarrhea, dehydration, hand-foot syndrome, hypertension and neutropenia disease. Therefore, there is the decision to stop clinical trials. Repeated assessments about toxicity and dose of the combination of drugs suggest that part of the adverse effects are dose-related , dose reduction may be tried to improve drug tolerance. In view of this conclusion, in 2009, the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) launched a cediranib clinical trail phase Ⅲ (BR29) for progressive NSCLC patients , the dose was adjusted to 20mg. The results have not been reported.
In 2009 ,European Society for Medical Oncology (ESMO) Annual report which is about cediranib treatment of metastatic renal cell carcinoma (referred mRCC) clinical trail phase II shows that cediranib treatment group tumor volume reducing rate is higher than the placebo group. Zurita tested Cediranib pretreatment serum cytokines and angiogenic factors ,and found that patients having low IL-10, VEGF, PIGF, SCF and MIG concentration during baseline time , have the more obvious tumor volume reduction after treatment.
The above information is edited by the chemicalbook of Tian Ye.
UsesCediranib (AZD2171) inhibited VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM, respectively.
Cediranib Preparation Products And Raw materials
Tag:Cediranib(288383-20-0) Related Product Information
4-FLUORO-5-HYDROXYINDOLE 6-Hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one 4-Fluoro-5-hydroxy-2-methylindole 6-METHOXYQUINAZOLIN-4-OL 4-Fluoro-5-methoxy-2-methyl-1H-indole Cediranib p-Anisidine POLY(ETHYLENE GLYCOL) METHYL ETHER ACRYLATE fluoro jade Methoxy Methoxydiethylborane m-Anisyl alcohol p-Anisaldehyde Anisole Methoxyacetic acid Guaiacol (Trifluoromethoxy)benzene 2-Methoxyethanol